Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eli Figueroa

Nurse Practitioner, Pediatrics Weston, FL Nurse Practitioner

NPI 1144513102 CMS profile 10690725

2900 S Commerce Pkwy, Weston, FL 33331

Open in the dashboard

General payments

$4,416

200 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eli Figueroa of Weston, FL is reported in the CMS Open Payments database as having received $4,416 across 200 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $494 22
2024 General $142 7
2023 General $1,524 69
2022 General $1,491 63
2021 General $764 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eli Figueroa
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Eli Figueroa were reported at $494. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Eli Figueroa Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $764 $60 $23–$142 $132
2022 $1,491 $72 $27–$161 $149
2023 $1,524 $89 $35–$185 $160
2024 $142 $93 $34–$199 $164
2025 $494 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $1,310 38 payments
  2. Jazz Pharmaceuticals Inc. $550 26 payments
  3. Neurelis, Inc. $452 24 payments
  4. Aquestive Therapeutics, Inc. $427 21 payments
  5. Corium, Inc. $350 19 payments
  6. Ironshore Pharmaceuticals Inc. $228 16 payments
  7. Supernus Pharmaceuticals, Inc. $193 12 payments
  8. Sumitomo Pharma America, Inc. $157 6 payments
  9. Sunovion Pharmaceuticals Inc. $117 6 payments
  10. LivaNova USA, Inc. $108 5 payments
  11. Other $524 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,416 200 payments
Products named General payments · program years 2021–2025
  1. Briviact $797 21 payments
  2. Epidiolex $550 26 payments
  3. VALTOCO $452 24 payments
  4. SYMPAZAN $403 20 payments
  5. Azstarys $350 19 payments
  6. Nayzilam $282 8 payments
  7. APTIOM $274 12 payments
  8. Fintepla $201 8 payments
  9. JORNAY PM $150 12 payments
  10. NURTEC ODT $127 7 payments
  11. Other $831 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

200 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record